Literature DB >> 10669651

Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations.

I Leviev1, R W James.   

Abstract

Paraoxonase (PON) is a serum enzyme with a wide species distribution. It protects lipoproteins from toxic oxidative modifications and is an antiatherogenic mechanism of major potential. Activity levels of PON are major determinants of the protective function; consequently, factors that influence PON levels are of particular relevance. The present study has identified 3 polymorphisms in the promoter region of the human PON1 gene. Cell transfection studies have revealed their variable impact on promoter activity, with up to 2-fold differences in reporter gene expression. Genotyping studies have established that the polymorphisms are frequent in the population, a finding that is consistent with a major impact on PON concentrations. The physiological relevance of the polymorphisms was underlined by showing that they are associated with highly significant differences in serum concentrations and activities of PON. The study thus firmly establishes a genetic basis for variations in serum PON levels and, consequently, serum PON activity. It is consistent with the suggestion that variations in a major antioxidant function of high density lipoprotein are, to an important degree, genetically determined.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10669651     DOI: 10.1161/01.atv.20.2.516

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  57 in total

Review 1.  Candidate genes and confirmed genetic polymorphisms associated with cardiovascular diseases: a tabular assessment.

Authors:  Z Tang; R P Tracy
Journal:  J Thromb Thrombolysis       Date:  2001-02       Impact factor: 2.300

Review 2.  Pharmacogenetics of paraoxonase activity: elucidating the role of high-density lipoprotein in disease.

Authors:  Daniel Seung Kim; Judit Marsillach; Clement E Furlong; Gail P Jarvik
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

Review 3.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

4.  Paraoxonase 1, 2 and 3 DNA variants and susceptibility to childhood inflammatory bowel disease.

Authors:  R Sanchez; E Levy; E Seidman; D Amre; F Costea; D Sinnett
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

5.  Matrix metalloproteinase-9 and paraoxonase 1 Q/R192 gene polymorphisms and the risk of coronary artery stenosis in Iranian subjects.

Authors:  Soudabeh Fallah; Morteza Seifi; Asghar Ghasemi; Mohsen Firoozrai; Ali Samadikuchaksaraei
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

Review 6.  The paraoxonase gene family and atherosclerosis.

Authors:  David Seo; Pascal Goldschmidt-Clermont
Journal:  Curr Atheroscler Rep       Date:  2009-05       Impact factor: 5.113

7.  Paraoxonase 1 (PON1) status and substrate hydrolysis.

Authors:  Rebecca J Richter; Gail P Jarvik; Clement E Furlong
Journal:  Toxicol Appl Pharmacol       Date:  2008-11-13       Impact factor: 4.219

8.  Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease.

Authors:  Angelika D Manthripragada; Sadie Costello; Myles G Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Epidemiology       Date:  2010-01       Impact factor: 4.822

Review 9.  Paraoxonase gene polymorphisms, oxidative stress, and diseases.

Authors:  Hong-Liang Li; De-Pei Liu; Chih-Chuan Liang
Journal:  J Mol Med (Berl)       Date:  2003-10-09       Impact factor: 4.599

10.  Human paraoxonase 1 hydrolysis of nanomolar chlorpyrifos-oxon concentrations is unaffected by phenotype or Q192R genotype.

Authors:  R Hunter Coombes; Edward C Meek; Mary Beth Dail; Howard W Chambers; Janice E Chambers
Journal:  Toxicol Lett       Date:  2014-08-02       Impact factor: 4.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.